Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A. van de Loosdrecht*, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. te MarveldeSergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subirá, Denise A. Wells, Marie C. Béné, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H.J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)
42 Downloads (Pure)

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Original languageEnglish
Pages (from-to)77-86
Number of pages10
JournalCytometry Part B - Clinical Cytometry
Volume104
Issue number1
Early online date13 Dec 2021
DOIs
Publication statusPublished - Jan 2023

Bibliographical note

Funding Information:
Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS-RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”.

Funding Information:
Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS‐RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”.

Funding Information:
Horizon 2020; European Union; Austrian Science Fund, Grant/Award Number: F4704 Funding information

Publisher Copyright:
© 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.

Fingerprint

Dive into the research topics of 'Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group'. Together they form a unique fingerprint.

Cite this